



ELSEVIER  
SAUNDERS

Otolaryngol Clin N Am  
41 (2008) 819–823

---

---

OTOLARYNGOLOGIC  
CLINICS  
OF NORTH AMERICA

---

---

## Index

*Note:* Page numbers of article titles are in **boldface** type.

### A

---

- Alcohol abuse, laryngeal cancer in,  
657–658, 678–679
- Angiogenesis, in pathogenesis of laryngeal  
cancer, 664
- Autofluorescence, laryngeal cancer and, 687

### B

---

- Biologic response modifiers, in squamous  
cell carcinoma of head and neck, 666

### C

---

- Cancer vaccines, in squamous cell cancer  
of head and neck, 667
- Carcinoma in situ, management of, 763
- Chemo- and radiation therapy, effects on  
swallowing, 807–811  
effects on voice, 805–807
- Chemoradiation, and organ preservation  
surgery, 741
- Chemotherapy, for supraglottic carcinoma,  
728–729  
for T4 lesions of laryngeal cancer,  
729–730
- Chondroma, of larynx, 712
- Chondrosarcoma, of larynx, 712
- Commissures, anterior, and posterior,  
tumors of, 702–703  
in glottic cancer, 763–764
- Computed tomography, to evaluate  
laryngeal cancer, 699–700  
versus magnetic resonance imaging,  
in laryngeal cancer, 682–683
- Conservation laryngeal surgery, 751–752
- Cricohyoido(epiglott)pexy, and partial  
supracricoid laryngectomy, in  
malignant lesions of larynx, 709–710
- Cytogenetics, in laryngeal cancer, 658–659

### D

---

- da Vinci Surgical Robot, 783, 785, 786, 787
- Dietary modifications, in dysphagia  
and laryngeal cancer, 810
- Dingman mouth gag, 785
- DNA hypermethylation, 660
- Dysphagia, laryngeal cancer and,  
compensatory strategies in, 810  
diet modifications in, 810  
exercises in, 809–810  
functional outcomes and, 807–808  
iatrogenic complications of,  
808–809  
instrumental assessment and, 808  
treatment of, 809

### E

---

- Electrolaryngeal speech, total laryngectomy  
and, 802
- Endolaryngeal surgery, 782
- Epidermal growth factor receptor, 661–662  
benefit of inhibiting, 663  
overexpression of, in glottic  
carcinoma, 662
- Epigenetic alterations, in laryngeal cancer,  
660–661
- Esophageal speech, total laryngectomy and,  
803
- Exercises, in dysphagia and laryngeal  
cancer, 809–810

### F

---

- Fluorescence in situ hybridization assays,  
in laryngeal cancer, 658–659

### G

---

- Genetic progression model, of laryngeal  
cancer, 658–660

- Glottic carcinoma, advanced,  
 chemotherapy for, 728–729  
     radiotherapy for, 728–732  
 anterior commissure in, 763–764  
 early, radiotherapy for, 718–726  
 in situ (Tis), 721  
 late, voice production and, 807  
 neck management in, 765–766  
 open surgical techniques in, 761  
 preoperative management in, 759  
 radiation in, dose of, 724–725  
 radiotherapy in, 762–763  
 staging of, 758–759  
 surgery in, 759–761  
 T1, 719–721  
 T2, 721–722  
     loco-regional control after  
     treatment for, 722–723  
 technical considerations in, 723–726  
 transoral laser microsurgery in,  
 760–761  
 treatment of, voice quality following,  
 721  
 voice quality in, 764–765
- Glottis, 698  
 malignant lesions of, staging of, 701

## H

---

- Head and neck, squamous cell carcinoma  
 of, 657
- Hemilaryngectomy, vertical,  
 and swallowing, 797–798  
     and voice, 797  
     in malignant lesions of larynx, 710
- Heterozygosity, loss of, test for, in laryngeal  
 cancer, 658–659
- Hypothyroidism, following radiotherapy,  
 736

## I

---

- Immune function, alterations of, in  
 squamous cell carcinoma of head  
 and neck, 665–667

## L

---

- Laryngeal cancer, advanced,  
 multidisciplinary approach in, 735  
     nodal disease in, management of,  
     730–731  
 alterations in tumor environment in,  
 663  
 altered protein expression in, 661–663  
 anatomic barriers of larynx and,  
 675–676

- angiogenesis in pathogenesis of, 664  
 autofluorescence and, 687  
 biology of, 674–675  
 biopsy in, 686  
 CT versus MRI in, 682–683  
 diagnosis and preoperative work-up  
 in, **673–695**  
 distant metastases of, 718  
 dysphagia and, compensatory  
     strategies in, 810  
     diet modifications in, 810  
     exercises in, 809–810  
     iatrogenic complications of,  
     808–809  
     instrumental assessment and, 808  
     treatment of, 809  
 early, radiotherapy in, complications  
 of, 735  
 early-stage, management of, **757–769**  
     cost of, 765  
 effects of, on voice and swallowing,  
**793–818**  
 endoscopy in, 686  
 epigenetic alterations in, 660–661  
 etiology of, 678–682  
 follow-up in, 689–690  
 genetic progression model of, 658–660  
 histology of, 689  
 history taking in, 677–678  
 imaging in, 682–683  
 immune evasion in, 665–667  
 incidence of, 657, 673  
 initial evaluation in, 677–678  
 intensity modified radiation therapy  
 in, advantages of, 732–734  
     cautions in use of, 734  
     plan for, 732, 733  
 laryngoscopy in, 680–681, 684–685  
 laser excision of, and voice, 794–796  
 local spread of, 716–717  
 loss of laryngeal function in, 673  
 medical history taking in, 679  
 metastatic work-up in, 684  
 minimally invasive treatments in,  
 794–797  
 molecular diagnosis of, 687–688  
 molecular genetics of, **657–672**  
 nodal metastases of, 717–718  
 open organ preservation surgery in,  
 745–750  
 operative assessment in, 684–685, 686  
 organ preservation surgery in, **741–755**  
     evaluation for, 743–745  
     principles of, 741–743  
 panendoscopy in, 685–686  
 patterns of spread of, 716–717  
 PET/CT in, 683  
 physical examination in, 679–680  
 postoperative radiation in, 731–732

- pulmonary status assessment in, 680
  - radiologic evaluation of, **697–713**
  - radiotherapeutic management of, **715–740**
  - recurrence of, conservation laryngeal surgery in, 751–752
  - rigid endoscopic evaluation in, 681–682
  - secondary primary tumor development in, 657
  - staging of, 688, 717
  - supraglottic, 678
  - T4 lesions, radiotherapy and chemotherapy for, 729–730
  - TNM staging in, 675, 690–692
  - transglottic, 676, 677
  - tumor thickness as prognostic in, 687
- Laryngeal surgery, anatomy of upper airway and, 781
- endoscopic, 781–782
  - robotics for, applications of, **781–791**
    - limitation of, 785
    - to enhance surgical precision, 790
  - potentials of, 783–784
- Laryngectomy, history of, 771
- horizontal supraglottic partial, in malignant lesions of larynx, 709
  - partial, 797
  - supracricoid, 801–802
    - and swallowing, 801–802
    - and voice, 801
    - contraindications to, 749
    - indications for, 749
  - partial, with cricohyoido(epiglott)pexy, in malignant lesions of larynx, 709–710
    - reconstruction in, 750, 751
    - surgical steps in, 749–750
  - supraglottic, 746–748
    - and swallowing, 798–800
    - and voice, 798
  - total, 802–805
    - adjuvant radiation with, 774–775
    - and electrolaryngeal speech, 802
    - and esophageal speech, 803
    - and swallowing and, 804–805
    - and tracheoesophageal speech, 803–804
    - cancer recurrence following, 776
    - complications of, 775–776
    - indications for, 771–772
    - neck and, 774
    - patient work-up and selection for, 772–773
    - primary and salvage, **771–780**
    - surgical technique for, 773–774
    - swallowing following, 776
    - tracheoesophageal speech following, 777
    - voice following, 776–777
    - vertical partial, 745–746
- Laryngoscope, volume limitations of, 785
- Laryngoscopy, in laryngeal cancer, 680–681, 684–685
- Larynx, anatomic barriers of, laryngeal cancer and, 676, 677
- anatomic levels of, 674
  - anatomy of, 715–716
  - chondroma of, 712
  - chondrosarcoma of, 712
  - imaging anatomy of, 697–699
  - imaging of, choosing modality of, 699–700
  - malignant lesions of, and staging of, 700–709
    - carotid artery involvement in, 708–709
    - cartilaginous invasion of, 705–707
    - horizontal supraglottic partial laryngectomy in, 709
    - lymph node staging in, 710–711
    - lymphatic drainage of larynx and nodal metastasis in, 710
    - pre-epiglottic and paraglottic space invasion by, 701–702
    - prevertebral involvement of, 708
    - prognostic indicators in, imaging findings as, 711
    - radiologic findings in, 709
    - resectability of, preoperative assessment of, 709
    - subglottic spread of, 704–705, 706
    - supracricoid partial laryngectomy with cricohyoido(epiglott)pexy in, 709–710
    - vertical hemilaryngectomy in, 710
  - metastatic disease of, 712
  - nonsquamous cell neoplasms of, 711–712
  - paraglottic space of, 676
  - pre-epiglottic space of, 676
- Laser microsurgery, transoral, in glottic cancer, 760–761
- Laser surgery, of laryngeal cancer, and swallowing, 796–797
  - and voice, 794–796, 796–797
 transoral, robotic surgery and, 787
- Lymph node staging, in malignant lesions of larynx, 710–711

Lymphatic drainage of larynx, in malignant lesions of larynx, 710

## M

Magnetic resonance imaging, computed tomography versus, in laryngeal cancer, 682–683  
to evaluate laryngeal cancer, 699–700

Microlaryngeal surgery, minimally invasive, 782  
limitations of, 783

Molecular diagnosis, of laryngeal cancer, 675, 690–692

## N

Neck, management of, in glottic cancer, 759–761  
total laryngectomy and, 774

Nonsquamous cell neoplasms, of larynx, 711–712

Nutrition, oral, 793

## O

OK-432, in squamous cell cancer of head and neck, 666–667

Organ preservation surgery, and chemoradiation, 741  
conservation, 751–752  
in laryngeal cancer, **741–755**  
evaluation for, 743–745  
principles of, 741–743  
open, in laryngeal cancer, 745–750

## P

Panendoscopy, in laryngeal cancer, 685–686

Papillomavirus, human, infection with, laryngeal cancer in, 658

Positron emission tomography/computed tomography, in laryngeal cancer, 683  
to evaluate laryngeal cancer, 699–700

## R

Radiologic evaluation, of laryngeal cancer, **697–713**

Radiotherapy, for glottic carcinoma, 718–726, 728–732, 762–763  
for subglottic carcinoma, 728–732  
for supraglottic carcinoma, 726–732  
for T4 lesions of laryngeal cancer, 729–730

in management of laryngeal cancer, **715–740**  
in verrucous carcinoma, 734–735  
intensity modified, in advanced cancer of larynx, 735  
in cancer of larynx, advantages of, 732–734  
cautions in use of, 734  
plan for, 732, 733  
with total laryngectomy, 774–775

Rigid endoscopic evaluation, in laryngeal cancer, 681–682

Robotic surgery, advantages of, 786–787  
and transoral laser surgery, 787  
cadaveric, 786

Robotics, for laryngeal surgery, applications of, **781–791**  
limitation of, 785  
to enhance surgical precision, 790  
potentials of, 783–784

## S

Sizofilan, in squamous cell carcinoma of head and neck, 666

Snakelike distal dexterity unit, 788–789

Squamous cell carcinoma, of head and neck, 657  
alterations of immune functions in, 665–667  
causative risk factors in, 657–658  
global hypomethylation in, 661  
vascular endothelial growth factor in, 664–665

Subglottis, 699  
malignant lesions of, staging of, 701

Supracricoid laryngectomy. See *Laryngectomy, supracricoid.*

Supraglottic carcinoma, advanced, chemotherapy for, 728–729  
radiotherapy for, 728–732  
early, radiotherapy for, 726–728  
nontraditional technique of, 727–728  
traditional technique of, 727

Supraglottic laryngectomy, 746–748

Supraglottis, 697–698  
malignant lesions of, staging of, 700–701

Swallowing, and voice, effects of laryngeal surgery on, 794  
chemo- and radiation therapy effects on, 807–811

dysfunction of, following  
chemoradiation, 736  
laser excision of laryngeal cancer  
and, 796–797  
supracricoid laryngectomy  
and, 801–802  
supraglottic laryngectomy  
and, 798–800  
total laryngectomy and, 804–805  
vertical hemilaryngectomy and,  
797–798

---

**T**

Thymostimulin, in squamous cell carcinoma  
of head and neck, 666  
TNM staging, in laryngeal cancer, 675,  
690–692  
Tobacco use, laryngeal cancer in, 657–658,  
678–679  
Tracheoesophageal speech, following total  
laryngectomy, 777, 803–804

---

**V**

Vascular endothelial growth factor, in  
squamous cell carcinoma of head  
and neck, 664–665

Verrucous carcinoma, radiotherapy in,  
734–735

Vertical partial laryngectomy, 745–746

Vocal folds, in laryngeal cancer, 757, 758

Voice, and swallowing, effects of laryngeal  
cancer on, **793–818**  
effects of laryngeal surgery on,  
794  
characteristics of, following organ  
preservation, 805–806  
chemo- and radiation therapy effects  
on, 805–807  
laser excision of laryngeal cancer and,  
794–796  
production of, and late glottic  
carcinoma, 807  
quality of, following glottic carcinoma,  
721  
supracricoid laryngectomy and, 801  
supraglottic laryngectomy and, 798  
therapy of, following organ  
preservation, 806–807  
vertical hemilaryngectomy and, 797

---

**X**

Xerostomia, following chemoradiation, 736